What happened to the Next Science (ASX:NXS) share price last earnings season?

Shares in the Aussie biotech were smashed on Friday before recovering late in the day

| More on:
A man scratches his head in confusion.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Next Science Ltd (ASX: NXS) share price has staged a remarkable recovery on Friday afternoon. Shares in the Aussie medical device company were down 4.1% before closing 1% higher at $1.48 per share despite no new announcements.

Next Science's half-year results release is looming on 30 August and investors will be watching the Aussie biotech closely.

Let's take a look at how the Aussie biotech company's shares have performed in previous earnings seasons.

What happened to the Next Science share price last earnings season?

Last earnings season was in February when Next Science reported its full-year earnings for the period ended 31 December 2021 (FY20).

The Aussie biotech reported earnings on 22 February including the below highlights:

  • Fourth quarter revenue growth up 75% compared to Q4 2019
  • Patent portfolio increased to 31 patents
  • 2 CE Marks awarded (Bactisure and BlastX)
  • Successful $15 million capital raised to fund the commercialisation of XPerience in the US and support long-term growth

The Next Science share price charged higher in the lead-up to (and immediately after) the earnings release. That included an 18.6% surge from February 18 through to February 24.

However, shares in the Aussie biotech didn't return to that $1.40 per share closing price level again until mid-April.

As it stands currently, the company has a market capitalisation of $293 million based on Friday's closing Next Science share price of $1.48 per share. The Aussie biotech share fell lower in June after it lowered earnings guidance for the second half of FY21.

Next Science said it is forecasting revenue of between $3.5 million and $4 million through to 30 June 2021. That was lower than initially predicted in the February earnings season with hopes for a similar growth trajectory to continue.

Foolish takeaway

The Next Science share price was smashed on Friday before pulling off a late-afternoon recovery. The ASX biotech share ultimately closed the day up 1% having been down 4.1% around lunchtime.

Investors will be hoping the group's half-year result on 30 August will be enough to kickstart the Aussie biotech share similar to what we saw in February.

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Next Science Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »